key: cord-0911598-uglmeyj3
authors: Fernández-Rojas, Miguel A.; Esparza, Marco A. Luna-Ruiz; Romero, Abraham Campos; Calva-Espinosa, Diana Y.; Moreno-Camacho, José L.; Langle-Martínez, Ariadna P.; García-Gil, Abraham; Solís-González, Claudia J.; Canizalez-Román, Adrián; León-Sicairos, Nidia; Alcántar-Fernández, Jonathan
title: Epidemiology of COVID-19 in Mexico, symptomatic profiles and presymptomatic people
date: 2021-01-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.086
sha: 5357b24b093463a0bb2d23c27e633c85b1d5cabd
doc_id: 911598
cord_uid: uglmeyj3

OBJECTIVES: The COVID-19 diagnosis is difficult and ambiguous due to nonspecific symptoms. Also, data from Mexico are hospitable population-based without signs and symptoms information. For these reasons, this work aims to provide epidemiology information about the burden of COVID-19 in the Mexican outpatients and to identify symptomatic COVID-19 profiles that could help in the early diagnosis of the disease. METHODS: Between June to September, epidemiological, clinical, and demographic data of 482,413 individuals diagnosed by RT-PCR test for SARS-CoV-2 in Salud Digna clinics were collected. RESULTS: We observed a 41% incidence of SARS-CoV-2 infections with a mean age of 36 years, being young adults (20-40 years) the most affected. Among occupations, deliverers (OR 1.38) or informal traders (OR 1.33) had a higher risk of COVID-19. Moreover, 13% of SARS-CoV-2 infections were in presymptomatic patients. Finally, we identify three different symptomatic profiles (common, respiratory, and gastrointestinal) associated with COVID-19. CONCLUSION: The incidence of SARS-CoV-2 was high among outpatients with a significant proportion of presymptomatic carriers, so it is necessary increasing testing and continue the SARS-CoV-2 surveillance with a better description of signs and symptoms; in this regard, were identified three symptomatic profiles that could help in the diagnose of COVID-19.

The initial reports showed that SARS-CoV-2 infection promotes pneumonia mainly in the older adults, which were the group with a major risk of getting hospitalized and getting Asymptomatic and presymptomatic carriers are terms commonly used indistinctly; however, they are not equivalent. By definition, asymptomatic carriers refer to individuals without symptoms but confirmed as SARS-CoV-2 positive by a laboratory test. On the other hand, presymptomatic carriers can be defined as cases with no symptoms at the moment of test, but they could develop later. For that reason, presymptomatic carriers only can be detected by retrospective studies (Nikolai et al., 2020; Savvides and Siegel, 2020) .

Several studies about this issue have shown that asymptomatic carrier's proportions ranged from 15 -45% (Nikolai et al., 2020) . These variations are due to age, presymptomatic status, On February 27th, 2020, the first case of COVID 19 in Mexico was detected. (Forster et al., 2020) . From this date, 1,255,974 confirmed cases of COVID 19 had been detected, with an overall mortality of 9%. Hypertension, obesity, and diabetes are the main comorbidities that increase death risk by COVID-19 (SSA, 2020). Mexico's information comes from the Health Ministry's mainly from hospital-based registries and shown a high incidence in men and people around 40 years; meanwhile, people with any comorbidity are more at risk to die by COVID-19 (Suárez et al., 2020) .

Detailed epidemiology profile of COVID-19 in the country is not readily available; also, the current COVID-19 diagnosis is ambiguous due to the lack of specificity of the symptoms (Struyf et al., 2020) . Moreover, the incidence of COVID-19 in outpatients, including presymptomatic and symptomatic, and their epidemiological profile remains unknown. For the above, we analyze epidemiological, clinical, and demographic data from 482,413 outpatients tested by RT-PCR for SARS-CoV-2 from 26 states of Mexico. Thus, we investigate the relevance of different factors and symptoms for SARS-CoV-2 infection to contribute epidemiology of COVID-19 in the country.

J o u r n a l P r e -p r o o f

The present work was a retrospective and transversal study. The collected data correspond to 482,413 outpatients of any sex and age evaluated for SARS-CoV-2 infection by PCR test in Salud Digna Clinics of 26 Mexican states from June 1st to September 30th. Only patients with confirmed positive or negative status from SARS-CoV-2 test, clinical and demographic information and that accept the use of their data by informed consent signing were considered. For geographical COVID-19 incidence analysis, we included states with 382 or more subjects. This threshold was considered from the sample size calculations for crosssectional studies (Pourhoseingholi et al., 2013) ; in this case, we use de general COVID-19 incidence (47%) reported by the Ministry of Health of Mexico in the same period of this study (Direccion General de Epidemiologia, 2020).

Nasopharyngeal swabs were collected in a viral transport medium to preserve samples until processing at the molecular biology laboratories at National Reference Center located in We applied a standardized survey previous to the SARS-CoV-2 PCR test to collect information regarding symptoms, clinical history, occupation, and lifestyle risk factors. PCR test results were according to manufacturer recommendations.

Information analyzed in this work belongs to patients who signed the informed consent for this study provided at the tests. A unique ID code was assigned to anonymize records for data privacy protection and prevent data duplication. Also, we aggregate information to enhance data protection. All procedures were carried out in adherence to the Mexican Federal Law on Personal Data Protection (LFPDPPP), the privacy policy of Salud Digna.

This study followed the approved guidelines for clinical information management, Helsinki's declaration, and Mexico's national regulations. This study was approved by the Ethical Review and Research Board of Salud Digna (SDI-2020-2).

According to the data type, we perform a χ 2 test for categorical variables expressed as frequencies or percentages. Continuous variables are shown as mean or median and interquartile ranges (IQR). Standardized rates were calculated with the direct method using the standard world population (Ahmad et al., 2000) ; standardization was made by age groups every ten years and sex for every 100 persons.

Age and sex-adjusted stepwise multivariate logistic regression were performed to evaluate the association between SARS-CoV-2 infection and potential risk factors (e.g., lifestyle).

To date, eleven symptoms are considered predictors of COVID-19 positiveness; however, some look little related between them or confusing clinicians. To determine the relevance of Subsequently, we calculate agreement between these groups by kappa index (Ki= 0.97). We tested Hartigan-Wong, Lloyd, Forgy, and MacQueen methods with 1,000 repetitions and 100,000 iterations for each one. Finally, we choose the MacQueen method for k-means due to it is better interclass inertia.

Finally, a p≤0.05 value was considered a statistically significant threshold in all tests.

Analyses were performed with SPSS 23 (SPSS Inc., Chicago, Ill., USA) or R 4.0.2 (CRAN project), and graphics were designed with GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA.).

This work includes data from 26 states (81%) of 32 states from Mexico, founding heterogeneous incidence of SARS-CoV-2 with at least one state per region with significantly higher incidence versus national incidence (Figure 1 A, Figure 2 ). Also, we observe that 14 states (54%) shown a statistically significant different incidence versus the national rate (38 per 100) (Supplementary Table 1 Table 1 ). The child population was sub represented due to government confinement measures (including closing schools) implemented since March 27th ( Figure 1C ).

The COVID-19 incidence was 41% (n= 196,738) with a median age of 37 years; the incidence was higher in males (51%) than females (49%) (p<0.0001), however, the male to female ratio was 1.02:1. (Table 1 ). Little more than half of the people (53%) were in contact with SARS-CoV-2 positive cases, being family members (56%) and co-workers (29%) the primary source of infection (Table 1) . Moreover, COVID-19 incidence in occupations like office workers (23%) and customer service workers (6%) was higher; however, occupations like deliverers (OR 1.38, 95% CI 1.29-1.48), informal traders (OR 1.33, 95% CI 1.29-1.37), and transport personal (OR 1.22 95% CI 1.18-1.26) shown a higher risk for SARS-CoV-2 infections than others (Supplementary Table 2 ). Among health and lifestyle factors, we observed that 10% of people were active smokers, 24% received the influenza vaccine, and the main comorbidities were Hypertension (6%), Diabetes (5%), and Obesity (2%) ( Table 1) .

To date, around 11 symptoms have been related to COVID-19, making their diagnosis very difficult because they are not specific to the disease. The main symptoms among people tested were headache (50%), arthralgia or myalgia (38%), and sore throat (36%) ( Table 2) .

No differences were found in symptoms incidence by sex or age. For the above, we performed a tandem clustering analysis to identify more related symptoms in confirmed COVID-19 cases to help healthcare workers to diagnose COVID-19 early. For these, we take remain cases (159,598) of SARS-CoV-2 positive cases after discarding presymptomatic people. This allowed us to identify three symptomatic groups associated with the incidence of COVID-19, who share headache, sore throat, and myalgia/arthralgia as frequent symptoms but differ between themselves due to other symptoms. We found an common cluster which was the most frequent (87,253= 56%) in which none of the symptoms is currently prominent, but has part of the core symptoms documented by the WHO (WHO, 2020a); the respiratory cluster (52,827= 34%) in which symptoms like fever (60%), cough (56%), chills (47%), J o u r n a l P r e -p r o o f runny nose (38%) and Breath difficulty (32%) highlights, and the gastrointestinal cluster (16,518= 10%) with a high frequency of diarrhea (74%), abdominal pain (63%) and vomit (49%) symptoms in respect of the other two profiles (Figure 3 A & B) .

Around 13% (25,520 cases) of SARS-CoV-2 positive patients had no symptoms on the test day and in the previous days. They were considered presymptomatic because they were not followed-up to determine if they were or not asymptomatics. The sex distribution of presymptomatic and symptomatic carriers shown significant differences (presymptomatic males vs. females p<0.0001; symptomatic males vs. females p<0.0001); on the other hand, presymptomatic carriers were more common among older adults than children, young people, and young adults (age< 10 = 26%, age 10-20 = 27%, age 21-40 =29%, age> 65 =31%) these differences were statistically significant (p<0.0001), a similar trend was observed in symptomatic cases. This age-specific trend of presymptomatic and symptomatic cases was statistically significant (p=0.0273, p<0.0001, respectively) ( Table 3) .

Moreover, symptomatic cases were more in contact with COVID-19 cases (20%) than presymptomatic (9%); also, family members with COVID-19 were more frequent among symptomatic (13%) than presymptomatic (6%). Moreover, non-communicable diseases (e.g., hypertension, diabetes, and obesity) were more prevalent in symptomatic than presymptomatic. Finally, smokers and influenza vaccination were more frequent in symptomatic than presymptomatic (Table 3) .

At present, the COVID-19 pandemic constitutes the most significant health challenge since H1N1 and MERS-CoV epidemics. After 11 months of Wuhan COVID 19 onset, over 71 million confirmed cases had been reported with a general mortality rate of 2% (WHO, 2020b). To date, America leads confirmed cases and death rates, which the US at the top (WHO, 2020b). Mexico is one of the countries with high SARS-CoV-2 incidences (43%), only behind Argentina (65%); meanwhile, other American countries with high confirmed cases like the US (~16 million cases) have lower incidence (7%) (WHO, 2020b). In this J o u r n a l P r e -p r o o f regard, Mexico's test rate for SARS-CoV-2 is 0.08% per thousand people versus 3% in the US or 0.43% in Argentina.

As a consequence, in Mexico has been reported high mortality (9%) per confirmed cases being 114,298 confirmed deaths by COVID-19, which is higher than other American countries (the US -2%, Argentina -3% or Brazil -3%) (WHO, 2020b). In addition, the temporal analysis between July 1st to September 30th showed that after reach a higher incidence in the second week in July (50%), this trend was reversed, showing a lower incidence (36%) by the end of September; however, a country level incidence remains higher (43%).

At the state level, Suarez and colleagues reported that after the first month of the COVID-19 pandemic in Mexico, the states with higher incidence were Mexico City, Mexico State, Baja California, Sinaloa, and Tabasco. This work shows that main metropolises like Mexico City have lower COVID-19 incidence while other states have ~18% more. Thus, as we can see, this data on the outpatients is similar to the hospitable database from the Mexican Health Ministry and point out that we need to make some refinements to actual pandemic management to reduce the incidence and mortality of COVID-19.

Differences in the pandemic's onset in each state, population density, the obedience of mitigation actions to reduce virus spread, and disparities between rural and urban populations could help understand the regional incidence of COVID-19 in the country (Suárez et al., 2020) . Similarly, in the US, people who live in rural areas have less access to the SARS-CoV-2 test than people who live in big cities like New York, which shows how the social, economic, and health discrepancies could impact the burden of COVID-19 (Souch and Cossman 2020). Likewise, in Mexico, the South and Occident regions have a higher vulnerability index than other regions, limiting their access to health services (Santana castañeda 2020).

The first reports of COVID-19 proposed different risks of being infected by the SARS-CoV-2 between sexes (Englmeier, 2020; de Groot and Bontrop, 2020); our results show a slight difference in the incidence of COVID-19 in females and males; however, the male to female incidence ratio was 1.02:1. The sex difference is more significant in mortality rate than in the J o u r n a l P r e -p r o o f incidence of COVID-19 (Peckham et al., 2020) . Thus, even with the evidence about higher amounts of ACE2 receptors in men and the lower number of receptors involved in innate immunity (Englmeier, 2020 ; de Groot and Bontrop, 2020), more epidemiological information is needed to clarify its relevance to COVID 19 etiology.

Similarly, an increase in COVID-19 severity has been associated with older people (Lusignan et al., 2020), while the risk of SARS-CoV-2 infection in this study was high in young adults.

In this study, around 77% were people under 50 years ( Figure 1B) ; this can be due to the population-age distribution in Mexico compared to other countries. De Souza and colleagues showed that other Latin-American countries like Brazil have a similar age-group distribution and found similar conclusions (Souza et al., 2020) . In addition to this, the infection in young adults could be because population groups around their thirties and forties are economically active, which means a higher exposure rate due to mobility (Amorim et al., 2020) .

In this way, we found that logistics, informal traders or delivery jobs have a higher risk of SARS-CoV-2 infection that could be explained by a high rate of people contact due to its activities. In occupations like office workers, customer service, and public servants, the risk is lower than other jobs might by mobility's reduction; however, we have no information about working modalities in the last group (home office or no). Furthermore, an increase in mobility is related to a higher risk of being infected, as seen in other countries, due to the relaxation of confinement measures.

Moreover, it is difficult to infer the viral infection's presence through the symptoms because they are not specific for COVID-19, which could confuse clinicians delaying the diagnosis.

For that reason, we perform a tandem clustering analysis to identify possible relationships among symptoms reported. We found three symptomatic profiles: patients with nonspecificity for any symptoms, others with mainly respiratory symptoms (Fever, Cough, Chills, Runny nose and Breath difficulty), and the last with gastrointestinal features (Diarrhea, Abdominal pain, and Vomit); this classification could help healthcare workers to improve the diagnosis and treatment of COVID-19. Unfortunately, due to our study's nature, we could not determine the relationship between symptomatic profiling and clinical outcomes. Therefore, more studies are needed to assess if these clusters could predict clinical outcomes of COVID-19.

Finally, one issue still controversial is the presymptomatic/asymptomatic patient's contribution to the SARS-CoV-2 spread. In this regard, the CDC pinpointed that one of the major SARS-CoV-2 infected people groups is asymptomatic. In the best-predicted scenario, these people have 75% efficiency to contagious other people (CDC, 2020). Metanalysis reports a proportion of asymptomatic people from 4% to 50% (Oran and Topol, 2020) . In this study, patients were not followed-up for any arising symptoms later, then people with SARS-CoV-2 positive test whose refers no symptoms at test day or previous days were considered as presymptomatic, which were about 13% of cases. Recent evidence in Korea shown that 36% of people analyzed was asymptomatic at the time of the PCR test, but 19% of these patients develop symptoms soon after the test, being virus transmitters even after three weeks (Lee et al., 2020) , which emphasize that lack of symptoms does not mean less transmission capacity. In addition, we found that the proportion of SARS-CoV-2 positive and presymptomatic people is higher in older people (31%) versus children (26%). Current evidence is controversial; some studies pointed out higher presymptomatic proportions in children versus older people arguing lower ACE2 receptor amounts in young people and less aggressive immune system response as an explanation of the high rate of presymptomatic children (He et al., 2020; Ma et al., 2020) ; however, other studies shown no significant differences between age groups and presymptomatic proportions (Jung et al., 2020; Yu et al., 2020) . Thus, more studies are necessary to characterize presymptomatic and asymptomatic carriers better, and increase testing could help identify them to reduce the virus spread.

This work provides a general insight into the burden of COVID-19 in the Mexican outpatients. It is important to note that we studied a self-selected population tested for SARS-CoV-2 infection, which involves a potential sub representation of subjects with specific features such as age (e.g., children) and jobs (e.g., healthcare workers).

Therefore, due to patients' lack of follow-up in this study, we could not accurately identify presymptomatic and asymptomatic people. Also, this study's information does not represent the Mexican population as a whole; however, this work and the hospital-based information could help us understand its pandemic's behavior.

Moreover, in the case of symptoms, they were self-reported by patients, which could mean that, in some cases, they could be misidentified that could impact our tandem clustering analysis. So, more studies in other populations are needed to enhance the knowledge of clinical manifestations of COVID-19.

In conclusion, we found a high SARS-CoV-2 incidence (41%), being young adults (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) years) the most affected. Also, we found a presymptomatic carrier's proportion of 13%, which increases with age; this could help implement triage in target populations to identify them and reduce virus spread. Furthermore, we identified three symptomatic COVID-19 profiles: common (56%), respiratory (34%), and gastrointestinal (10%) that we expected could help clinicians diagnose COVID-19 early. Further studies are needed to determine if these profiles could predict a patient's clinical outcomes.

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. ; the red color indicates the gastrointestinal cluster, gold shows the respiratory cluster, and blue shows the common cluster (no symptoms stand out). Dimension 1 (Dim 1) and Dimension 2 (Dim 2) shows the variance explained by each one (22.2, and 9.4%, respectively). Panel B shows the frequency and distribution of COVID-19 related symptoms in each cluster identified. Symptoms are indicated as follow: 1=Conjunctivitis, 2= Abdominal pain, 3= Headache, 4= Sore throat, 5= Myalgia/Arthralgia, 6= Breath difficulty, 7= Diarrhea, 8= Chills, 9= Fever, 10= Runny nose, 11= Constant dry cough, and 12= Vomit).

J o u r n a l P r e -p r o o f 

Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro

Prevalencia de diabetes y descontrol glucémico en México: resultados de la Ensanut

risk of infection and hospitalization by Covid-19 in Mexico: a case-control study

Cancer registration: principles and methods. Statistical methods for registries

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis

Hipertensión arterial en adultos mexicanos: prevalencia, diagnóstico y tipo de tratamiento

COVID-19)

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

Age-dependent effects in the transmission and control of COVID-19 epidemics

Sitio oficial COVID-19 México Dirección General de Epidemiología -Gobierno Federal

A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly

Phylogenetic network analysis of SARS-CoV-2 genomes

Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases

COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males?

Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis

Clinical Characteristics of Asymptomatic Patients with COVID-19: A Nationwide Cohort Study in South Korea

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a crosssectional study

Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan

Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible

Health risks -Overweight or obese population -OECD Data

Prevalence of Asymptomatic SARS-CoV-2 Infection

Sample size calculation in medical studies

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review

Epidemiological and clinical characteristics of the early phase of the COVID-19 epidemic in Brazil

SSA. COVID-19 -Coronavirus 2020

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease

Epidemiology of COVID-19 in Mexico: From the 27th of February to the 30th of

WHO 2020a. WHO Coronavirus Disease (COVID-19) Coronavirus disease

WHO 2020b. WHO Coronavirus Disease (COVID-19) Dashboard 2020

Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study

Note: Age groups was defined by decades, with the exception of <20 and >60. a) Total n=482,413, b) Missing values= 3,807; c) Missing values= 43,807of people (%) a,b Positive SARS-CoV-2 (%) *

09) (30.57-31.61) ns 64,279 (45.31) (45.06-45.58) <0.0001 >65 1,359 (31.21) (29.84-32.59) ref

Age groups were defined as children (<10), young people (10-20), young adults (21-40), adults (41-65), and older adults (>65). € The trend of age-specific incidence was evaluated with the chi-squared (χ2) test for trend and was statistically significant in presymptomatic (p<0.0273) and symptomatic (p<0.0001). a Missing values: Presymptomatic= 9